[go: up one dir, main page]

PE20051035A1 - Hormonas de administracion transdermica que no necesitan potenciadores de penetracion - Google Patents

Hormonas de administracion transdermica que no necesitan potenciadores de penetracion

Info

Publication number
PE20051035A1
PE20051035A1 PE2004001230A PE2004001230A PE20051035A1 PE 20051035 A1 PE20051035 A1 PE 20051035A1 PE 2004001230 A PE2004001230 A PE 2004001230A PE 2004001230 A PE2004001230 A PE 2004001230A PE 20051035 A1 PE20051035 A1 PE 20051035A1
Authority
PE
Peru
Prior art keywords
preventional
transdermal administration
hormones
penetration enhancers
treatment
Prior art date
Application number
PE2004001230A
Other languages
English (en)
Inventor
Thomas Langguth
Stefan Bracht
Michael Dittgen
Dirk Schenk
Petra Huber
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34924031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20051035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20051035A1 publication Critical patent/PE20051035A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION DE ADMINISTRACION TRANSDERMICA QUE COMPRENDE: A) UNA CAPA TRANSPARENTE DE GESTODENO O UN ESTER DEL MISMO; B) UNO O MAS EXCIPIENTES ACEPTABLES PARA USO FARMACEUTICO SELECCIONADO DE POLIISOBUTILENOS, POLIBUTENOS, POLIISOPRENOS, ENTRE OTROS. LA CAPA CONTIENE ADEMAS UN ADHESIVO SELECCIONADO DE RESINAS DE HIDROCARBURO, RESINAS DE COLOFONIA, ENTRE OTROS. DICHA COMPOSICION PERMITE MANTENER NIVELES EN PLASMA DE GESTODENO RELATIVAMENTE ALTOS DURANTE UN PERIODO DE TIEMPO PROLONGADO, SIENDO EFECTIVOS PARA INHIBIR LA OVULACION EN LA MUJER O COMO ALTERNATIVA PARA EL TRATAMIENTO DE LA ENDOMETRIOSIS, SINDROME PREMENSTRUAL, TRASTORNOS DEL CLIMATERIO, PREVENCION DE LA OSTEOPOROSIS, REGULACION O ESTABILIZACION DEL CICLO MENSTRUAL
PE2004001230A 2003-12-12 2004-12-10 Hormonas de administracion transdermica que no necesitan potenciadores de penetracion PE20051035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078881 2003-12-12

Publications (1)

Publication Number Publication Date
PE20051035A1 true PE20051035A1 (es) 2006-02-08

Family

ID=34924031

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001230A PE20051035A1 (es) 2003-12-12 2004-12-10 Hormonas de administracion transdermica que no necesitan potenciadores de penetracion

Country Status (23)

Country Link
EP (2) EP2138169B1 (es)
CN (1) CN101843603B (es)
AR (1) AR046762A1 (es)
AT (1) ATE457168T1 (es)
CR (1) CR8465A (es)
CY (2) CY1110637T1 (es)
DE (1) DE602004025444D1 (es)
DK (2) DK2138169T3 (es)
ES (2) ES2340925T3 (es)
GT (1) GT200400262A (es)
HN (1) HN2004000526A (es)
HR (2) HRP20100254T1 (es)
JO (1) JO2606B1 (es)
ME (1) ME01069B (es)
MY (2) MY144053A (es)
PE (1) PE20051035A1 (es)
PL (2) PL2138169T3 (es)
PT (2) PT2138169E (es)
RS (2) RS51260B (es)
SI (2) SI1541137T1 (es)
SV (1) SV2006001970A (es)
TW (1) TWI257299B (es)
UA (1) UA89766C2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1594483E (pt) 2003-02-21 2006-12-29 Schering Ag Penso transdérmico estável aos uv
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
WO2010042610A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
CA2740002C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
CA2740005C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
HRP20170292T1 (hr) 2010-09-06 2017-04-21 Bayer Intellectual Property Gmbh Transdermalni flasteri niske doze s visokim otpuštanjem lijeka
HK1204287A1 (en) * 2012-01-27 2015-11-13 敏捷治疗公司 Transdermal hormone delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4081537A (en) 1975-10-10 1978-03-28 Schering Aktiengesellschaft Δ15 -Steroids and pharmaceutical compositions thereof
JP3238389B2 (ja) * 1988-10-27 2001-12-10 シエーリング アクチエンゲゼルシヤフト ゲストデン含有の経皮適用のための薬剤
PT99338A (pt) 1990-10-29 1992-10-30 Alza Corp Processo para a preparacao de composicoes de farmacos anticoncepcionais administradas transdermicamente contendo uma mistura dum estrogeno e gestodeno e dispositivos para a sua administracao transdermica
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
EP1242012B1 (en) 1999-11-24 2009-12-30 Agile Therapeutics, Inc. Improved transdermal contraceptive delivery system and process
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use

Also Published As

Publication number Publication date
CN101843603B (zh) 2012-06-27
PT1541137E (pt) 2010-05-17
ATE457168T1 (de) 2010-02-15
CN101843603A (zh) 2010-09-29
EP2138169A3 (en) 2011-04-06
EP1541137B1 (en) 2010-02-10
CR8465A (es) 2007-06-06
HK1074801A1 (en) 2005-11-25
PL1541137T3 (pl) 2010-07-30
JO2606B1 (en) 2011-11-01
ES2340925T3 (es) 2010-06-11
CY1110637T1 (el) 2015-04-29
EP1541137A3 (en) 2005-11-16
CY1115064T1 (el) 2016-12-14
MY152750A (en) 2014-11-28
DK1541137T3 (da) 2010-04-26
MY144053A (en) 2011-08-15
ME01069B (me) 2012-10-20
HRP20140077T1 (hr) 2014-02-28
EP1541137A2 (en) 2005-06-15
EP2138169B1 (en) 2013-11-06
PL2138169T3 (pl) 2014-04-30
DE602004025444D1 (de) 2010-03-25
DK2138169T3 (da) 2013-11-18
AR046762A1 (es) 2005-12-21
SV2006001970A (es) 2006-02-16
HK1132682A1 (en) 2010-03-05
HRP20100254T1 (hr) 2010-06-30
HN2004000526A (es) 2010-02-01
ES2445690T3 (es) 2014-03-04
RS51260B (sr) 2010-12-31
TWI257299B (en) 2006-07-01
RS53182B (sr) 2014-06-30
GT200400262A (es) 2005-10-31
TW200528073A (en) 2005-09-01
SI1541137T1 (sl) 2010-06-30
EP2138169A2 (en) 2009-12-30
UA89766C2 (en) 2010-03-10
SI2138169T1 (sl) 2014-03-31
PT2138169E (pt) 2014-02-17

Similar Documents

Publication Publication Date Title
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
PE20051035A1 (es) Hormonas de administracion transdermica que no necesitan potenciadores de penetracion
MX2023009011A (es) Inhibidor de cdk.
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
EA201400543A1 (ru) Способы и композиции для чрескожной доставки
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
PE20020348A1 (es) Exemestano como agente quimiopreventivo
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
HN2006020928A (es) "composiciones de tanaproget que contienen etinil estradiol"
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
MX393613B (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
EA201590907A1 (ru) Усиленные полиамином составы для ионтофореза соединения триптана
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CO2022009510A2 (es) Compuestos activos frente a receptores nucleares
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
CU20100143A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
ATE382356T1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
AR095691A1 (es) FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO
BR112022011284A2 (pt) Composição tópica e métodos de medição da capacidade de resfriamento de uma composição tópica
TW200509863A (en) Irradiation device for medical use
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
PE20220250A1 (es) Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma

Legal Events

Date Code Title Description
FG Grant, registration